Shares of specialty pharmaceutical company Avenue Therapeutics, Inc. (ATXI) are rising 3 percent on Thursday's trading continuing their upward trend since the past few days.
The stock has been on the rise since it recently received the official meeting minutes from the FDA regarding a meeting conducted for IV Tramadol in combination with other opioid analgesics to manage moderate-to-moderately severe pain.
Currently at $6.66, the stock has traded between $3.00 and $27.75 during the past 52 weeks.
For comments and feedback contact: editorial@rttnews.com
Business News